Forma Therapeutics, Janssen Biotech ink drug discovery agreement
As per the alliance, Forma will be responsible for the discovery and development of drugs against a range of tumor metabolism targets and will be entitled to receive
The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression.